SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : A Biotech Bash - Recs and Wrecks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Andrew H who wrote (114)9/2/1997 12:31:00 PM
From: scaram(o)uche   of 171
 
You do no credit to this thread by making light of serious questions. All companies are subject to becoming over-valued relative to other biotechs. It happened with Ligand 15 months ago. An industry-wide perspective will help with insight, and Jongmans' question is relevant. If you look at the history of LGND-related posts at m.i.s and here at SI, you will see that they accelerated as LGND hit market caps which were not subsequently sustained. That is, an increased frequency of LGND-related posts _has_ been a contrary indicator for near-term profit. Henry says that he considers it difficult to "time" stocks, and that he has a long-term perspective. Those are valid considerations.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News